
BiBBInstruments AB – Receives intention of subscription regarding warrants of series TO 1 from management and board members

BiBBInstruments AB ("BiBB" or the "Company") announces today that the Company has received intention of subscription from six members of its management and board of directors regarding the exercise of warrants of series TO 1 (the "Warrants" or "TO1"). The intention of subscription amounts to a total of approximately SEK 0.5 million, corresponding to approximately 6 percent of the outstanding TO1.

BiBB announces today that the Company has received intention of subscription from six members of the Company's management and board of directors regarding the exercise of TO1. The intention of subscription amounts to a total of approximately SEK 0.5 million, corresponding to approximately 6 percent of the outstanding TO1.

The subscription period continues until and including June 5, 2025 and the subscription price amounts to SEK 3.25 per share. Complete terms and conditions for the Warrants are available on the Company's website: www.bibbinstruments.com.

Advisors

DNB Carnegie SME and Setterwalls Advokatbyrå AB acted financial and legal advisors to BiBB in connection with the Rights Issue.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:

Fredrik Lindblad, CEO

E-mail: fredrik.lindblad@bibbinstruments.com

Phone: +46 70 899 94 86

www.bibbinstruments.com

About BiBB

BiBBInstruments AB ("BiBB") develops and manufactures EndoDrill® – the world's first market-cleared, powered biopsy instrument for endoscopy. EndoDrill® enables rapid and high-quality core needle biopsies (CNB) for the diagnosis of serious cancers, including gastric, pancreatic, liver, lung, and bladder cancer. The product portfolio targets the fast-growing global market for endoscopic ultrasound-guided biopsy instruments (EUS/EBUS). EndoDrill® GI is FDA-cleared and CE-marked, with U.S. launch starting in 2025 in collaboration with TaeWoong Medical USA. EndoDrill® EBUS and EndoDrill® URO were CE-marked in 2024 and are planned for gradual launch. BiBB was founded by Dr Charles Walther and is headquartered at Medicon Village in Lund, Sweden. The share (BiBB) is listed on Spotlight Stock Market.

BiBBInstruments AB
Press release, May 30, 2025



Scheelevägen 2
Medicon Village
SE-223 81 Lund
www.bibbinstruments.com

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in BiBB. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in BiBB has only been made through the prospectus published by BiBB on December 19, 2024.